<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363972</url>
  </required_header>
  <id_info>
    <org_study_id>01-0014-01</org_study_id>
    <nct_id>NCT02363972</nct_id>
  </id_info>
  <brief_title>Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD</brief_title>
  <official_title>Ellipsys Vascular Access Catheter System Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a&#xD;
      less invasive means of establishing vascular access to facilitate dialysis in patients with&#xD;
      end stage renal disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maturation Success Rate at 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Maturation success rate of the access site was a binary endpoint defined as (1) achievement of a venous diameter of greater than or equal to 4 mm and (2) blood flow greater than or equal to 500 ml/min as measured via duplex ultrasound at the 90 day follow-up visit for the ITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Device-related Serious Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>The primary safety endpoint was defined as the percent of subjects having one or more of the following device-related serious adverse events: vessel perforation, vessel dissection, and electrical shock during index; and significant embolization in a previously uninvolved arterial territory within 90 days of the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Access Systems That Successfully Created an AVF</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of Ellipsys Vascular Access Systems that successfully created an AVF upon deployment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites With Clinical Patency at Discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites that demonstrated physical exam patency through clinic discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites That Sustain 2-needle Cannulation by 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites that could sustain three 2-needle cannulations at the prescribed needle gauge and blood flow rate (Qb) between the 4 week and 90 day follow-up visits after initial AV fistula creation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites That Achieved or Maintained Maturation at 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites which achieved or maintained maturation following intervening manipulations (surgical or endovascular) designed to promote or reestablish maturation. This definition also includes common definition for secondary patency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites That Achieved Maturation Without Intervention</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites that achieved and maintained maturation without any surgical or endovascular intervention designed to promote or reestablish maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites That Were Patent Following Intervention</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites which were patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Access Sites That Achieved Patency Without Intervention</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of access sites that maintained patency without any surgical or endovascular intervention designed to maintain or reestablish blood flow in the access site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Rate</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of subjects who had one or more surgical or endovascular interventions to maintain or reestablish blood flow in the access site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transposition Rate</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of subjects who required one or more surgical transpositions performed to facilitate needle access</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to First AVF Cannulation</measure>
    <time_frame>90 days</time_frame>
    <description>Time to AVF cannulation was defined as the elapsed time to the first use of access site (from the date of the study procedure).</description>
  </other_outcome>
  <other_outcome>
    <measure>Catheter Utilization</measure>
    <time_frame>90 days</time_frame>
    <description>Catheter utilization was defined as the total number of days a catheter was used before access site maturation per subject. The start date was either 1) the date of the study procedure, for subjects who already had a dialysis catheter in place or 2) the date placed, if during the study. The end date was either 1) the date the catheter was removed or 2) the 90 day visit, if the catheter was still in place.</description>
  </other_outcome>
  <other_outcome>
    <measure>Target Vessel Location</measure>
    <time_frame>90 days</time_frame>
    <description>Anatomic location of matured target vessel</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>AV Fistula</condition>
  <condition>Fistula</condition>
  <condition>End Stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ellipsys Vascular Access Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ellipsys Vascular Access Catheter</intervention_name>
    <description>A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
    <arm_group_label>Ellipsys Vascular Access Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients were eligible for enrollment into the study if they met the following criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years of age and ≤ 80 years of age&#xD;
&#xD;
          2. Male or non-pregnant female (verified with a urine/blood pregnancy test, for women of&#xD;
             reproductive potential)&#xD;
&#xD;
          3. Life expectancy of at least one year, per the investigator's opinion&#xD;
&#xD;
          4. Diagnosed with end-stage renal disease (ESRD) or chronic kidney disease requiring&#xD;
             dialysis or anticipated start of dialysis within 6 months of enrollment&#xD;
&#xD;
          5. Patients deemed medically eligible for upper extremity autogenous AV fistula creation,&#xD;
             per institutional guidelines and/or clinical judgment&#xD;
&#xD;
          6. Adequate quality vein based on pre-operative assessment&#xD;
&#xD;
               1. Adjacent vein diameter of ≥ 2.0 mm at target anastomosis site&#xD;
&#xD;
               2. Confirmed clinically significant outflow&#xD;
&#xD;
          7. Adequate quality radial artery based on pre-operative assessment&#xD;
&#xD;
             a. Arterial lumen diameter of ≥ 2.0 mm at target anastomosis site&#xD;
&#xD;
          8. Adequate collateral arterial perfusion&#xD;
&#xD;
               1. Patent palmar arch&#xD;
&#xD;
               2. Negative Allen's Test for ulnar artery insufficiency&#xD;
&#xD;
          9. No clinical evidence of subclavian artery stenosis on the ipsilateral side.&#xD;
&#xD;
         10. Radial artery-adjacent vein proximity ≤ 1.5 mm measured lumen edge-to-lumen edge as&#xD;
             determined by pre-procedural ultrasound and confirmed pre-procedure&#xD;
&#xD;
         11. Patient was able to provide written informed consent&#xD;
&#xD;
         12. Able to travel to enrolling institution for follow-up examinations&#xD;
&#xD;
         13. Able and willing to follow a daily aspirin and/or other anti-coagulation/antiplatelet&#xD;
             regimen, not including warfarin (Coumadin, or comparable anti-coagulant, see exclusion&#xD;
             criteria 15)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients were excluded if any of the following was true:&#xD;
&#xD;
          1. Documented or suspected central venous stenosis including upper extremity arterial&#xD;
             stenosis (≥ 50%)&#xD;
&#xD;
          2. a. Prior vascular surgery at or proximal (central) to the AVF target site b. Prior&#xD;
             axillary dissection or mastectomy on the ipsilateral side as intended AV fistula site&#xD;
&#xD;
          3. History of steal syndrome from a previous hemodialysis vascular access on the&#xD;
             ipsilateral side which required intervention or abandonment&#xD;
&#xD;
          4. Evidence of vascular disease at the radial artery/adjacent vein site on the&#xD;
             ipsilateral side&#xD;
&#xD;
          5. Pre-existing vascular disease that could confound the study results&#xD;
&#xD;
          6. Systolic pressures &lt; 100 mm Hg at the time of screening&#xD;
&#xD;
          7. Suspected or confirmed skin disease at the skin entry site&#xD;
&#xD;
          8. Immunocompromised patients (e.g. HIV positive)&#xD;
&#xD;
          9. Edema of the upper extremity on the ipsilateral side&#xD;
&#xD;
         10. Patients requiring immunosuppressant therapy such as sirolimus (Rapamune®) or&#xD;
             Prednisone at a dose of &gt; 10 mg per day&#xD;
&#xD;
         11. Peripheral white blood cell count &lt; 1.5 K/mm3 or platelet count &lt; 75,000 cells/mm3&#xD;
&#xD;
         12. Current diagnosis of carcinoma (defined as in remission &lt; 1 year)&#xD;
&#xD;
         13. Pregnant or currently breast feeding&#xD;
&#xD;
         14. Known bleeding diathesis or coagulation disorder&#xD;
&#xD;
         15. Receiving warfarin (Coumadin, or comparable anti-coagulant) therapy&#xD;
&#xD;
         16. Patients with acute or active infection&#xD;
&#xD;
         17. Scheduled kidney transplant within 6 months of enrollment&#xD;
&#xD;
         18. Participation in another clinical investigation (excluding retrospective studies or&#xD;
             studies not requiring a consent form)&#xD;
&#xD;
         19. History of substance abuse or anticipated to be non-compliant with medical care or&#xD;
             study requirements based on investigator judgment&#xD;
&#xD;
         20. Patient required creation of an arteriovenous fistula distal to the wrist&#xD;
&#xD;
         21. Patient required nerve block requiring immobilization of the arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Vascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Vascular Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BNMG San Diego Vascular Access Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Nephrology Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Kidney Disease Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Vascular Center</name>
      <address>
        <city>North Chesterfield</city>
        <state>Virginia</state>
        <zip>23236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ellipsys Vascular Access Catheter</title>
          <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ellipsys Vascular Access Catheter</title>
          <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maturation Success Rate at 90 Days</title>
        <description>Maturation success rate of the access site was a binary endpoint defined as (1) achievement of a venous diameter of greater than or equal to 4 mm and (2) blood flow greater than or equal to 500 ml/min as measured via duplex ultrasound at the 90 day follow-up visit for the ITT population.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Maturation Success Rate at 90 Days</title>
          <description>Maturation success rate of the access site was a binary endpoint defined as (1) achievement of a venous diameter of greater than or equal to 4 mm and (2) blood flow greater than or equal to 500 ml/min as measured via duplex ultrasound at the 90 day follow-up visit for the ITT population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Device-related Serious Adverse Events</title>
        <description>The primary safety endpoint was defined as the percent of subjects having one or more of the following device-related serious adverse events: vessel perforation, vessel dissection, and electrical shock during index; and significant embolization in a previously uninvolved arterial territory within 90 days of the index procedure.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Device-related Serious Adverse Events</title>
          <description>The primary safety endpoint was defined as the percent of subjects having one or more of the following device-related serious adverse events: vessel perforation, vessel dissection, and electrical shock during index; and significant embolization in a previously uninvolved arterial territory within 90 days of the index procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Access Systems That Successfully Created an AVF</title>
        <description>Percent of Ellipsys Vascular Access Systems that successfully created an AVF upon deployment</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Access Systems That Successfully Created an AVF</title>
          <description>Percent of Ellipsys Vascular Access Systems that successfully created an AVF upon deployment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites With Clinical Patency at Discharge</title>
        <description>Percent of access sites that demonstrated physical exam patency through clinic discharge</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites With Clinical Patency at Discharge</title>
          <description>Percent of access sites that demonstrated physical exam patency through clinic discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites That Sustain 2-needle Cannulation by 90 Days</title>
        <description>Percent of access sites that could sustain three 2-needle cannulations at the prescribed needle gauge and blood flow rate (Qb) between the 4 week and 90 day follow-up visits after initial AV fistula creation</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (65) is a subset of of the overall number of participants analyzed (103) due to not all participants being on dialysis an requiring 2 needle cannulation by the 90 day outcome measure time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites That Sustain 2-needle Cannulation by 90 Days</title>
          <description>Percent of access sites that could sustain three 2-needle cannulations at the prescribed needle gauge and blood flow rate (Qb) between the 4 week and 90 day follow-up visits after initial AV fistula creation</description>
          <population>The analysis population analyzed (65) is a subset of of the overall number of participants analyzed (103) due to not all participants being on dialysis an requiring 2 needle cannulation by the 90 day outcome measure time frame</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites That Achieved or Maintained Maturation at 90 Days</title>
        <description>Percent of access sites which achieved or maintained maturation following intervening manipulations (surgical or endovascular) designed to promote or reestablish maturation. This definition also includes common definition for secondary patency.</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites That Achieved or Maintained Maturation at 90 Days</title>
          <description>Percent of access sites which achieved or maintained maturation following intervening manipulations (surgical or endovascular) designed to promote or reestablish maturation. This definition also includes common definition for secondary patency.</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites That Achieved Maturation Without Intervention</title>
        <description>Percent of access sites that achieved and maintained maturation without any surgical or endovascular intervention designed to promote or reestablish maturation</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites That Achieved Maturation Without Intervention</title>
          <description>Percent of access sites that achieved and maintained maturation without any surgical or endovascular intervention designed to promote or reestablish maturation</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites That Were Patent Following Intervention</title>
        <description>Percent of access sites which were patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites That Were Patent Following Intervention</title>
          <description>Percent of access sites which were patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Access Sites That Achieved Patency Without Intervention</title>
        <description>Percent of access sites that maintained patency without any surgical or endovascular intervention designed to maintain or reestablish blood flow in the access site</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Access Sites That Achieved Patency Without Intervention</title>
          <description>Percent of access sites that maintained patency without any surgical or endovascular intervention designed to maintain or reestablish blood flow in the access site</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Rate</title>
        <description>Percent of subjects who had one or more surgical or endovascular interventions to maintain or reestablish blood flow in the access site</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Rate</title>
          <description>Percent of subjects who had one or more surgical or endovascular interventions to maintain or reestablish blood flow in the access site</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transposition Rate</title>
        <description>Percent of subjects who required one or more surgical transpositions performed to facilitate needle access</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Transposition Rate</title>
          <description>Percent of subjects who required one or more surgical transpositions performed to facilitate needle access</description>
          <population>The analysis population analyzed (102) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to First AVF Cannulation</title>
        <description>Time to AVF cannulation was defined as the elapsed time to the first use of access site (from the date of the study procedure).</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (33) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not requiring cannulation by the 90 day outcome timeframe</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First AVF Cannulation</title>
          <description>Time to AVF cannulation was defined as the elapsed time to the first use of access site (from the date of the study procedure).</description>
          <population>The analysis population analyzed (33) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not requiring cannulation by the 90 day outcome timeframe</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Catheter Utilization</title>
        <description>Catheter utilization was defined as the total number of days a catheter was used before access site maturation per subject. The start date was either 1) the date of the study procedure, for subjects who already had a dialysis catheter in place or 2) the date placed, if during the study. The end date was either 1) the date the catheter was removed or 2) the 90 day visit, if the catheter was still in place.</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (32) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not requiring a catheter utilization by the 90 day outcome timeframe</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Catheter Utilization</title>
          <description>Catheter utilization was defined as the total number of days a catheter was used before access site maturation per subject. The start date was either 1) the date of the study procedure, for subjects who already had a dialysis catheter in place or 2) the date placed, if during the study. The end date was either 1) the date the catheter was removed or 2) the 90 day visit, if the catheter was still in place.</description>
          <population>The analysis population analyzed (32) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not requiring a catheter utilization by the 90 day outcome timeframe</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Target Vessel Location</title>
        <description>Anatomic location of matured target vessel</description>
        <time_frame>90 days</time_frame>
        <population>The analysis population analyzed (90) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not achieving an identifiable target vein by the 90 day outcome timeframe</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipsys Vascular Access Catheter</title>
            <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Location</title>
          <description>Anatomic location of matured target vessel</description>
          <population>The analysis population analyzed (90) is a subset of of the overall number of participants analyzed (103) due to not all participants having a patent fistula at discharge from the index procedure and not achieving an identifiable target vein by the 90 day outcome timeframe</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cephalic vein</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Basilic vein</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brachial vein 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brachial vein 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>Serious Adverse Events and Other Adverse Events were monitored/assessed without regard to the specific Adverse Event Term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ellipsys Vascular Access Catheter</title>
          <description>ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.&#xD;
Ellipsys Vascular Access Catheter: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine, metabolic nutritional serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Uncoded</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular, blood and lymphatic serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eye, ear nonserious events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune, infection nonserious events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Drug effect nonserious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal nonserious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin nonserious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical procedure nonserious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular, blood nonserious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gene Reu EVP and General Manager</name_or_title>
      <organization>Avenu Medical</organization>
      <phone>9492762483</phone>
      <email>greu@avenumedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

